217 related articles for article (PubMed ID: 14737089)
41. Efficacy and limitations of cyclophosphamide-induced tolerance against alphaGal antigen.
Shimizu I; Tomita Y; Iwai T; Kajiwara T; Okano S; Sueishi K; Nomoto K; Yasui H
Scand J Immunol; 2005 Sep; 62(3):271-80. PubMed ID: 16179014
[TBL] [Abstract][Full Text] [Related]
42. Adenovirus-mediated expression of pig alpha(1, 3) galactosyltransferase reconstructs Gal alpha(1, 3) gal epitope on the surface of human tumor cells.
Xing L; Xia GH; Fei J; Huang F; Guo LH
Cell Res; 2001 Jun; 11(2):116-24. PubMed ID: 11453543
[TBL] [Abstract][Full Text] [Related]
43. Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy.
Forman D; Tian C; Iacomini J
Mol Ther; 2005 Aug; 12(2):353-9. PubMed ID: 15939670
[TBL] [Abstract][Full Text] [Related]
44. Application of cyclophosphamide-induced tolerance in alpha1,3-galactosyltransferase knockout mice presensitized with Gal alpha 1-3Gal beta-4-GlcNAc antigens.
Onzuka T; Shimizu I; Tomita Y; Iwai T; Okano S; Tominaga R
Surg Today; 2008; 38(9):807-14. PubMed ID: 18751946
[TBL] [Abstract][Full Text] [Related]
45. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters.
Galili U; Tibell A; Samuelsson B; Rydberg L; Groth CG
Transplantation; 1995 Jun; 59(11):1549-56. PubMed ID: 7539957
[TBL] [Abstract][Full Text] [Related]
46. Intragraft gene expression profile associated with the induction of tolerance.
Doki T; Mello M; Mock D; Evans JM; Kearns-Jonker M
BMC Immunol; 2008 Feb; 9():5. PubMed ID: 18267024
[TBL] [Abstract][Full Text] [Related]
47. Immunity to islet grafts transduced with adenovirus vectors does not inhibit long-term islet function.
Cheng J; Sun J; Sung RS
Transpl Immunol; 2009 May; 21(1):33-42. PubMed ID: 19224710
[TBL] [Abstract][Full Text] [Related]
48. Gene therapy to inhibit xenoantibody production using lentiviral vectors in non-human primates.
Fischer-Lougheed JY; Tarantal AF; Shulkin I; Mitsuhashi N; Kohn DB; Lee CC; Kearns-Jonker M
Gene Ther; 2007 Jan; 14(1):49-57. PubMed ID: 16886002
[TBL] [Abstract][Full Text] [Related]
49. Immunological property of antibodies against N-glycolylneuraminic acid epitopes in cytidine monophospho-N-acetylneuraminic acid hydroxylase-deficient mice.
Tahara H; Ide K; Basnet NB; Tanaka Y; Matsuda H; Takematsu H; Kozutsumi Y; Ohdan H
J Immunol; 2010 Mar; 184(6):3269-75. PubMed ID: 20173026
[TBL] [Abstract][Full Text] [Related]
50. A study of the xenoantigenicity of neonatal porcine islet-like cell clusters (NPCC) and the efficiency of adenovirus-mediated DAF (CD55) expression.
Omori T; Nishida T; Komoda H; Fumimoto Y; Ito T; Sawa Y; Gao C; Nakatsu S; Shirakura R; Miyagawa S
Xenotransplantation; 2006 Sep; 13(5):455-64. PubMed ID: 16925670
[TBL] [Abstract][Full Text] [Related]
51. Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold.
Lei TC; Su Y; Scott DW
Cell Immunol; 2005 May; 235(1):12-20. PubMed ID: 16098495
[TBL] [Abstract][Full Text] [Related]
52. The α-Gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation.
Galili U
Biochimie; 2001 Jul; 83(7):557-63. PubMed ID: 11522383
[TBL] [Abstract][Full Text] [Related]
53. Fetal porcine thymus engraftment, survival and CD4 reconstitution in alphaGal-KO mice is impaired in the presence of high levels of antibodies against alphaGal.
Rodriguez-Barbosa JI; Zhao Y; Houser S; Zhao G; Sykes M
Xenotransplantation; 2003 Jan; 10(1):24-40. PubMed ID: 12535223
[TBL] [Abstract][Full Text] [Related]
54. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
55. Glucose intolerance in a xenotransplantation model: studies in alpha-gal knockout mice.
Dahl K; Buschard K; Gram DX; d'Apice AJ; Hansen AK
APMIS; 2006 Nov; 114(11):805-11. PubMed ID: 17078862
[TBL] [Abstract][Full Text] [Related]
56. Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines.
Galili U; Wigglesworth K; Abdel-Motal UM
J Immunol; 2007 Apr; 178(7):4676-87. PubMed ID: 17372027
[TBL] [Abstract][Full Text] [Related]
57. Anti-Gal antibody-mediated skin graft rejection requires a threshold level of Gal expression.
Murray-Segal L; Gock H; Cowan PJ; d'Apice AJ
Xenotransplantation; 2008 Feb; 15(1):20-6. PubMed ID: 18333910
[TBL] [Abstract][Full Text] [Related]
58. Soluble Galalpha(1,3)Gal conjugate combined with hDAF preserves morphology and improves function of cardiac xenografts.
Brandl U; Erhardt M; Michel S; Jöckle H; Burdorf L; Bittmann I; Rössle M; Mordstein V; Brenner P; Hammer C; Reichart B; Schmoeckel M
Xenotransplantation; 2007 Jul; 14(4):323-32. PubMed ID: 17669174
[TBL] [Abstract][Full Text] [Related]
59. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
60. Ablation of undifferentiated human embryonic stem cells: exploiting innate immunity against the Gal alpha1-3Galbeta1-4GlcNAc-R (alpha-Gal) epitope.
Hewitt Z; Priddle H; Thomson AJ; Wojtacha D; McWhir J
Stem Cells; 2007 Jan; 25(1):10-8. PubMed ID: 16960131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
